| Today's Big NewsOct 11, 2022 |
| By Kevin Dunleavy During a parliament hearing in Germany investigating Europe's vaccine supply negotiations with Pfizer, a company executive who participated in the talks emphatically denied that they were conducted by way of text message between Pfizer CEO Albert Bourla and EC President Ursula von der Leyen. |
|
|
|
By Max Bayer Michelle McMurry-Heath is resigning as CEO of BIO days after the Wall Street Journal reported on internal clashes between her and the organization's board. Former BIO board chair and co-founder of GlycoMimetics Rachel King has been named interim CEO. |
By Heather Landi Two new reports confirm that physician burnout and turnover rates remain dangerously high due to the rising toll of stress during the COVID-19 pandemic and resulting staffing shortages. Here's what provider organizations and medical groups should focus on to help stem the tide of burnout, attrition and a worsening clinician shortage. |
By Conor Hale The project will explore whether applying AI to DNA and other omics sequencing data can increase their returns in successful biological targets and promising drug candidates. |
By Fraiser Kansteiner It has been a tumultuous few months for Gilead Sciences’ breast cancer med Trodelvy. But after a surprise comeback at ESMO this year that reignited blockbuster hopes for the franchise, the antibody-drug conjugate is keeping its winning streak rolling. |
By Max Bayer Days after PureTech confirmed speculation of a merger with Nektar, conversations between the two companies have ceased, for now. PureTech says its original statement created the impression that the talks were farther along than they were. |
By Frank Diamond Healthcare systems around the world facing the challenge of diagnosing long COVID might benefit by separating the symptoms of the disease into three general clusters. |
By Andrea Park Fitbit’s wearable health trackers can be used to monitor daily activity, sleep patterns, heart rate, blood oxygen levels, skin temperature and, as of last month, possible signs of atrial fibrillation—and, now, all of those round-the-clock measurements could help support those recovering from substance abuse. |
By Kevin Dunleavy Less than a week after acquiring two biotechs, Ginkgo Bioworks has scored a deal with Merck to bolster its active pharmaceutical ingredient manufacturing. Specializing in synthetic biology, Ginkgo will engineer biocatalytic enzymes for Merck’s use in its drug manufacturing processes. |
By Gabrielle Masson Eli Lilly is forecasting that Nimbus Therapeutics will discover new therapies for treating metabolic diseases, partnering up with the biotech and giving it the chance to collect up to $496 million in biobucks. |
By Dave Muoio The $150 million deal and accompanying $220 million initial capital investment will expand access to integrated care, support educational programs and add 2,300 jobs across Louisiana, the organizations say. |
By Andrea Park In a case of life imitating orthopedics, Orthofix and SeaSpine—makers of devices to heal bone fractures and bridge gaps in the spine—will fuse together in what they’ve termed a merger of equals. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about trial results for Eisai and Biogen's Alzheimer’s drug, which were surprisingly good, and we dig into what comes next. We also discuss how Pfizer is ramping up its DTC ad campaign for its COVID shots, most recently spending big on a booster ad for the NFL season. |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Given the wide array of post transcriptional and post translational regulatory processes that govern cellular dynamics, additional omics types are needed to capture a more comprehensive understanding of the molecular landscape of a tumor.Register now to learn more. 
|
|
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
